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The structure and dynamics of bacterial communities in the airways
of persons with cystic fibrosis (CF) remain largely unknown. We
characterized the bacterial communities in 126 sputum samples
representing serial collections spanning 8–9 y from six age-matched
male CF patients. Sputum DNA was analyzed by bar-coded pyrose-
quencing of the V3–V5 hypervariable region of the 16S rRNA gene,
defining 662 operational taxonomic units (OTUs) from >633,000
sequences. Bacterial community diversity decreased significantly
over time in patients with typically progressive lung disease but
remained relatively stable in patients with a mild lung disease phe-
notype. Antibiotic use, rather than patient age or lung function, was
the primary driver of decreasing diversity. Interpatient variability in
community structure exceeded intrapatient variability in serial sam-
ples. Antibiotic treatment was associated with pronounced shifts in
community structure, but communities showedboth short- and long-
term resilience after antibiotic perturbation. There was a positive
correlation between OTU occurrence and relative abundance, with
a small number of persistent OTUs accounting for the greatest abun-
dance. Significant changes in community structure, diversity, or total
bacterial density at the time of pulmonary exacerbation were not
observed. Despite decreasing community diversity in patients with
progressive disease, total bacterial density remained relatively stable
over time. These findings show the critical relationship between air-
way bacterial community structure, disease stage, and clinical state
at the time of sample collection. These features are the key param-
eters with which to assess the complex ecology of the CF airway.
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Chronic infection and inflammation of the airways are theleading causes of morbidity and mortality in cystic fibrosis
(CF). Therefore it is reasonable to expect that a better under-
standing of airway infection in CF could provide opportunities for
novel strategies to maintain lung health in this population. Re-
cently, themicrobiota of the CF airways has been assessed through
the application of culture-independent methods that leverage the
phylogenetic information of the bacterial 16S rRNAgene. By using
a variety of techniques, including Sanger sequencing of clone li-
braries (1, 2), terminal restriction fragment length polymorphism
analysis (3, 4), microarray hybridization (5, 6), or pyrosequencing
(7), these studies have revealed the presence of a farmore complex
bacterial community in the airways of CF patients than previously
appreciated with culture-based methods.
Most of these studies have been cross-sectional, analyzing
samples collected at a single time point from individual patients.
Correlations between microbial communities and disease pro-
gression in cross-sectional studies can be confounded by a host
of variables, including patient age, sex, lung disease stage, and
antibiotic use. Longitudinal studies that analyze serial samples
obtained from individual patients over long periods of time allow
better assessment of the impact of these potentially confounding
variables in constructing tractable models of the relationship
between the dynamics of the lung microbial community and dis-
ease progression (4, 8).
In this study, we used a culture-independent approach to in-
vestigate intensively the dynamics of the CF airway bacterial
communities over the course of 8–9 y in six age- and sex-matched
CF patients. The findings reveal a dynamic ecological system that
is influenced markedly by a patient’s rate of disease progression
as well as by disease stage and clinical state at the time of
sampling. These features have significant bearing on measures
of diversity and community structure, reinforcing the power of
longitudinal studies in relating the status of the airway microbial
community to CF disease activity.
Results
Patients and Lung Microbiota Measures. Multiple sputum samples
were collected from six adult male patients with CF during the
course of 8–9 y. Percent predicted forced expiratory volume in 1
s (%FEV1) was used as a measure of lung function. Three
patients (S1, S2, and S3) showed a mild phenotype of lung dis-
ease, maintaining relatively stable lung function over several
years. The other three patients (P1, P2, and P3) had a more
typical course of CF lung disease, exhibiting a progressive decline
in lung function during the period of observation. Hereafter
these two groups of patients are referred to as “stable” and
“progressing” patients, respectively (Table 1 and Fig. 1A).
The bacterial communities in 126 sputum samples obtained
from these six patients were profiled using pyrosequencing of the
16S rRNA V3–V5 hypervariable region. A total of 633,746 high-
quality reads were generated from these samples with an average
of 5,030 reads per sample. From these sequences, 662 opera-
tional taxonomic units (OTUs) (based on 97% DNA sequence
similarity) were identified. On average, 36 OTUs per sample
were detected; however, the range was large (5–114 OTUs per
sample). After normalization to the sample with the smallest
number of reads (1,152), 259 OTUs were included in further
analyses. Among these, 47 OTUs each had a relative abundance
of more than 1% in at least one sputum sample (Table S1).
Community Diversity Relative to Disease Progression and Clinical State.
The diversity of the bacterial community, based on calculation of
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the Shannon index, fluctuated in serial samples from all patients
but remained relatively constrained in the three stable patients
(S1, S2 and S3). In contrast, serial samples from the three pro-
gressing patients (P1, P2 and P3) exhibited statistically significant
decreases in community diversity during the course of several
years (Fig. 1B).
CF is characterized by periods of relatively stable pulmonary
function punctuated by episodic exacerbations of respiratory
symptoms and decreased lung function which usually warrant an-
tibiotic treatment. To examine the impact of these changes in
clinical state on bacterial diversity, each of the 126 samples was
assigned to one of four “BETR” categories: baseline (B); pulmo-
nary exacerbation before initiation of episodic antibiotic therapy
(E); antibiotic treatment of pulmonary exacerbation (T); and
recovering from pulmonary exacerbation (R) (Table 2). Eight
samples with insufficient medical record information were labeled
as “unknown” (U). Not unexpectedly, a comparison of the diversity
of bacterial communities revealed that treatment samples, col-
lected when patients were receiving antibiotics for exacerbation,
were significantly less diverse than baseline, exacerbation, or re-
covering samples (Fig. 1C). No significant differences in diversity
levels were observed between baseline and exacerbation samples,
whereas diversity levels from recovering samples were significantly
lower than those from exacerbation samples.
Impacts of Age, Antibiotic Therapy, and Lung Function on Diversity.
Having demonstrated that clinical state at the time of sample
collection influences measures of community diversity, we next
sought to assess the relative impacts of patient age, lung function,
and antibiotic therapy on diversity. Antibiotic load was quantified
as the sum of the number of days a patient received antibiotics
(prescribed for maintenance therapy as well as for acute treat-
ment of pulmonary exacerbations) during the 30 d before speci-
men collection (see SI Materials and Methods for details). In the
three stable patients, the diversity of the community did not de-
crease significantly with increasing age and mildly decreasing lung
function (Fig. 1B); similarly, no significant decrease in diversity
was observed after adjustment for antibiotic load. In contrast,
in the three progressing patients, where increasing age and de-
creasing lung function were each associated with decreasing di-
versity, adjustment for antibiotic load eliminated or diminished
the statistical significance of these trends (Fig. S1).
Samples from all six patients were combined to explore further
the effects of age, lung function, and antibiotic load on diversity in
both univariate and multivariate linear mixed models (Table S2).
In the univariate models, all three variables were correlated in-
dividually with decreasing diversity. In the multivariate model,
however, antibiotic use was the strongest predictor of decrease in
diversity, overshadowing the contributions of age and lung func-
tion to contribute to a significant trend (P < 0.001 for antibiotic
load; P> 0.10 for age and lung function; see SI Results for details).
Collectively, these results indicated that antibiotic use, rather than
patient age or lung function, was the primary driver of the de-
creasing bacterial diversity observed in patients with typically
progressive CF lung disease.
Community Structure Dynamics. We compared community struc-
tures across patients to determine if interindividual differences in
structure exceeded the changes we observed between serial sam-
ples from the same patient. Pairwise ecologic distances were cal-
culated for all samples using the Bray–Curtis (BC) distancemetric,
which takes into account both communitymembership and relative
abundance. These distances then were visualized by principal co-
ordinate analysis (PCoA), which showed considerable overlap
between communities from the two sets of stable and progressing
patients (Fig. 2A). However, in comparing patient pairs, PCoA
revealed appreciably distinct communities in individual patients
(Fig. S2). Likewise, analysis of molecular variance (AMOVA) (9)
showed significant differences in communities between all patient
pairs, except between patients P2 and P3.
BC-based PCoA plots of communities from individual patients
also showed the impact of clinical state on the dynamics of
community structure (Fig. 2B). The majority of sputum samples
from the three stable patients were collected during baseline
states, and communities clustered in limited areas of PCoA plots.
In contrast, the three progressing patients experienced more
exacerbations and more courses of antibiotic treatment. Baseline
and exacerbation samples from these patients clustered in the
left half of the PCoA plots, whereas samples collected during
antibiotic treatment drifted into other areas, particularly in
patients P1 and P3. PCoA using the Jaccard distance metric,
which takes into account only community membership, revealed
similar results (Fig. S3).
The significance of the relationships between the structure of
the bacterial community (measured as BC distance), patient age,
%FEV1, and antibiotic load was assessed using the Mantel test.
The positive correlation between BC distance and antibiotic load
was greater (Mantel r = 0.32, P < 0.01) than that between BC
distance and age (Mantel r = 0.20, P < 0.01) or between BC
distance and %FEV1 (Mantel r = 0.22, P < 0.01). When antibi-
otic load was used as a control in a partial Mantel test, lesser
correlations between BC distance and age (Mantel r = 0.11, P =
0.02) and between BC distance and %FEV1 (Mantel r= 0.12, P <
0.01) were observed.
Communities in samples obtained after recovery from treat-
ment of exacerbation were closer to the baseline and exacerbation
(preantibiotic) communities in the ordination than were samples
obtained during antibiotic treatment, suggesting resiliency of
communities after antibiotic perturbation. For example, sample
10 from patient P1 (Fig. 2B) was obtained at baseline, and sample
Table 1. Study subjects
Stable patients Progressing patients
S1 S2 S3 P1 P2 P3
CFTR genotype Unknown* ΔF508/1717–1G > A ΔF508/ΔF508 ΔF508/ΔF508 ΔF508/ΔF508 ΔF508/ΔF508
Age range 18.9–28.0 21.2–30.1 19.8–28.1 21.1–29.2 18.7–27.3 22.0–30.1
Observation period (y)† 9.1 8.9 8.3 8.1 8.6 8.1
%FEV1 range 81–83 83–88 91–82 68–30 65–41 77–25
Avg. %FEV1 change
‡ 0.11 0.56 −1.11 −4.69 −2.79 −6.42
No. specimens 23 14 13 20 30 26
*No mutations identified from the 70 mutation sequencing panel, which includes ΔF508. CF diagnosis based on positive sweat chloride
test.
†Years between collection dates of first and last sputum samples.
‡Calculated as the difference between %FEV1 values when first and last sputum samples were collected divided by the observation
period.
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11 was obtained 15 wk later during treatment for an exacerbation.
Sample 12 was collected after return to baseline 11 wk thereafter
and resided close to sample 10 on the PCoA plot. Resiliency over
the course of several years also was suggested by PCoA. In patient
P2, for example, the community in the last collected sample,
obtained during recovery from treatment for exacerbation, clus-
tered close to the first sample, collected during baseline 8.5 y
earlier. Similarly, the last samples obtained during periods with-
out antibiotic treatment in patient P1 (sample 13, collected 7.5 y
after the first sample) and in patient P3 (sample 12, collected 6.5 y
after the first sample) also resided close to their respective first
samples (Fig. 2B).
OTU Occurrence and Relative Abundance. The occurrence and rel-
ative abundance of OTUs were dynamic in serial samples from
both stable and progressing patients (Fig. 3, Fig. S4, and Table
S1), but differences between these groups were noted. The most
pronounced difference was with Staphylococcus, which occurred
in 67% of samples from progressing patients but in only 6% of
samples from stable patients.
Within each patient’s set of serial samples, certain OTUs were
characterized as persistent, being defined as detected with a rela-
tive abundance of >1% in at least 50% of the samples obtained
from that individual throughout the 8–9 y of observation. Pseu-
domonas was detected in at least 92% of samples in each patient
(Table S1). Species in the S. milleri group were found in at least
58% of samples from each patient, and species in the S. mitis group
were detected in at least 65% of samples from all patients except
patient P3. A positive relationship was found between OTU oc-
currence and relative abundance. Although only 10 (3.9%) of the
259 total OTUs detected in the 126 sputum samples were defined
as persistent (i.e., were found in more than 50% of samples in at
least one of the six patients), these taxa accounted for 83–90% of
the total relative abundance in each patient (Table S3).
Clinical state, particularly treatment of exacerbation, affected
the occurrence and relative abundance of OTUs. In patient P3,
for example, S. mitis group species were detected in 46% of all
samples; however, they were detected in only 15% of samples
obtained during treatment for exacerbation and in 86% of sam-
ples obtained at exacerbation before initiation of antibiotic
therapy. In all three progressing patients, more OTUs were
characterized as persistent when only samples obtained at base-
line or exacerbation were considered (Table S3). In other words,
in the absence of antibiotic treatment or recovery from treatment,
more OTUs (primarily anaerobic species) met the criteria for
being considered persistent in these patients.
The effects of repeated courses of antibiotic therapy for ex-
acerbation were especially evident in later stages of lung disease,
in which communities were heavily dominated by one or two
OTUs (Fig. 3 and Fig. S4). In patient P1, communities late in the
disease course were heavily dominated by Achromobacter and
Pseudomonas, with these two OTUs accounting for up to 99.9%
A
B
C
Fig. 1. Changes in lung function and community diversity. (A) Percent
predicted FEV1 values (y axis) are plotted against patient age (x axis).
Patients S1, S2, and S3 have relatively stable disease; patients P1, P2, and P3
have progressive disease. Solid circles indicate the ages when the first and
last sputum samples were obtained. (B) Temporal changes in community
diversity in stable (Upper Row) and progressing (Lower Row) patients. In
each plot, community diversity measured by Shannon index is plotted
against patient age when sputum was collected. (C) Boxplot comparison of
microbial diversity in sputum samples obtained during different BETR clinical
states. The top and bottom boundaries of each box indicate 75th and 25th
quartile values, respectively, and black lines inside each box represent 50th
quartile (median) values. Ends of the whiskers mark the lowest and highest
diversity index in each BETR category. The letters above the boxes indicate
comparison results in group means; groups with the same letter do not have
significant differences in means, but those indicated by different letters are
significantly different. (See SI Results for details.)
Table 2. BETR categories
Clinical state Description
Baseline (B) Well or mild increase in pulmonary symptoms
Not a doctor defined pulmonary exacerbation
Not hospitalized for increase in pulmonary
symptoms
Not on episodic antibiotics for >30 d
May or may not be on maintenance antibiotics
Exacerbation (E) Doctor defined pulmonary exacerbation or
increased pulmonary symptoms fitting definition
of exacerbation*
Before start of episodic IV or oral antibiotics
Not on episodic antibiotics for >30 d
May or may not be on maintenance antibiotics
Treatment (T) On IV or oral episodic antibiotics for treatment
of doctor defined exacerbation or increased
pulmonary symptoms fitting definition
of exacerbation*
Recovering (R) Off episodic antibiotics ≤30 d
May or may not be on maintenance antibiotics
May or may not be back to baseline clinical state
*See SI Materials and Methods for details.
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of the relative abundance in some samples. In patients P2 and
P3, communities in later samples were dominated by Pseudo-
monas, nearly to the exclusion of other OTUs.
Quantitation of Bacterial Load. Bacterial densities in samples were
calculated by quantitative PCR analysis using a universal 16s
rRNA primer-probe assay. No significant differences in total
bacterial densities were detected in sputum samples from in-
dividual patients or from the three stable patients compared with
the three progressing patients (Fig. S5A; P > 0.05, linear mixed
model). Similarly, bacterial density did not differ significantly
between samples based on clinical BETR state (Fig. S5B; P >
0.05, linear mixed model).
Discussion
Previous cross-sectional studies have reported that bacterial
community diversity in CF is correlated positively with pulmonary
function and inversely with patient age, suggesting a role for
community composition in the pathophysiology of CF airway
disease (5, 6). In our longitudinal study, we, too, found a positive
correlation between diversity and lung function; however, at the
individual patient level, decreasing community diversity was not
necessarily correlated with increasing age. In the three patients
with a mild lung disease phenotype, community diversity re-
mained quite stable throughout time spans of 8–9 y. Furthermore,
in patients S1 and S2, community diversity levels were compara-
ble to those observed late, during periods of advanced lung dis-
ease, in the three progressing patients (Fig. 1B). Thus, community
diversity alone is not a sufficient indicator of disease status. Of
particular note is patient S3, who was homozygous for the ΔF508
CF transmembrane conductance regulator allele, a genotype more
commonly associated with a more aggressive lung disease phe-
notype. Despite having relatively mild lung disease, this patient
had airway bacterial communities that were significantly more
diverse than those in the other two stable patients and compa-
rable to those observed in early samples from the three pro-
gressing patients (Fig. 1B and Fig. S6). This apparent correlation
between community diversity and CF genotype raises intriguing
questions about the role the ΔF508 allele plays in susceptibility
to airways infection.
Schluchter and colleagues (10) characterized CF lung disease
phenotype by using longitudinal pulmonary function data, dem-
onstrating the advantages of this approach over the use of a single
FEV1 measurement to describe the severity of a patient’s lung
disease at a particular point in time. More recently, Konstan and
colleagues (11) used these same principles to clarify the distinction
between a patient’s overall CF lung disease severity phenotype
(lung disease aggressiveness) and that patient’s current state of
lung disease (lung disease stage). The rate at which %FEV1
declines over a period is an indicator of the aggressiveness of
a patient’s lung disease, independent of the stage of the patient’s
lung disease, which is defined as “early” when serial %FEV1
measures are >70; “intermediate” when %FEV1 measures range
between 70 and 40; and “advanced” when %FEV1 measures are
<40. In this context, the three stable patients included in our study
can be described as having a mild lung disease-aggressiveness
phenotype, and the three progressing patients represent a more
typical moderate lung disease-aggressiveness phenotype (Fig. S7).
A
B
Fig. 2. PCoA of bacterial community structures using BC distances. (A)
Community structures of samples from three stable patients (blue) and three
progressing patients (red). Distances between symbols on the ordination
plot reflect relative similarities in community structures. PC1, principal co-
ordinate 1; PC2, principal coordinate 2. (B) Community structure dynamics in
serial samples highlighting the patient’s clinical state on day of collection.
The scale and percent of variation explained by PC1 and PC2 for each plot
are the same as shown in A. Upper row shows stable patients (S1, S2, S3);
lower row shows progressing patients (P1, P2, P3). Circles represent in-
dividual sputum samples and are color coded to reflect BETR category (B,
blue; E, red; T, green; R, yellow; U, gray); lines connect serial samples. Up-
right and inverted triangles indicate first and last samples, respectively, in
each serial set. Samples 10–13 from patient P1 and sample 12 from patient
P3 are indicated by black arrows and are described in the text.
B B B E E TE E R T R B E R T R R T R T R T R T E R T T R R
18 26 28 3022 2420
0 146
Bogoriella-1
Haemophilus
Prevotella-3
Bogoriella-2
Leptotrichia Sphingobacterium
Pseudomonas-1
Streptococcus-1
Streptococcus-2
Veillonella
Prevotella-1
Gemella
Fusobacterium
Rothia
Granulicatella
Neisseria-1
Porphyromonas-1
Prevotella-1
Staphylococcus
Capnocytophage-1
Abiotrophia
Capnocytophaga-2
Actinobacillus
Oribacterium
Pasteurella
Prevotella-4
Bacteroides
All other OTUs
10
40
50
60
70
80
90
10
0
30
20
0%
 R
el
at
iv
e 
A
bu
nd
an
ce
 o
f O
TU
P2
1010109108107<107
Fig. 3. Relative abundance of OTUs in serial sputum samples from patient P2.
Relative abundances of OTUs, each accounting for >1% of the total bacterial
community, are shown in each sample. Relative abundances of all remaining
OTUs, each representing ≤1% of the community, are shown in gray at the top
of each bar. Top line indicates patient age at time of sample collection. Letters
beneath each bar indicate BETR category (Table 2). Heat map indicates anti-
biotic load (Materials and Methods) at the time of sputum sample collection.
Circles indicate total bacterial density (16S rRNA copies/mL sputum) based on
quantitative PCR. Similar graphs for patients S1, S2, S3, P1, and P3 are shown in
Fig. S4. Pseudomonas-1 represents Pseudomonas aeruginosa. Streptococcus-1
represents species within the Streptococcus mitis group. Streptococcus-2 rep-
resents species within the Streptococcus milleri group.
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Our study demonstrates that among patients with moderately
aggressive lung disease, disease stage (early, intermediate, or ad-
vanced), as indicated by %FEV1 measures, has significant bearing
on estimates of the diversity of the lung bacterial community. As
the three (stable) patients with mildly aggressive lung disease ul-
timately progress from early to intermediate stages of disease, and
as antibiotic therapy intensifies, a similar decrease in diversity likely
would be observed; however, continued long-term follow-up of
these patients will be necessary to demonstrate this decrease.More
importantly, our results show that clinical state (BETR category) at
the time of sample collection has a pronounced effect on measures
of diversity. It remains to be determined how finer-scale demar-
cation of clinical state (e.g., subcategories taking into account the
exact number of days on or off antibiotic therapy relative to sample
collection) might further impact measures of community diversity.
The pathophysiologic bases for the intermittent exacerbations
that characterize CF are poorly understood. Speculation has
focused on presumed acute changes in the composition of the
airways bacterial community around the time of exacerbation.
Although we detected significantly lower community diversity in
samples obtained during antibiotic treatment, we observed no
differences in diversity between baseline samples obtained dur-
ing periods of relatively stable health and samples obtained at
the time of exacerbation but before initiation of antibiotic
therapy. This lack of a clear microbial signature for the onset of
exacerbation suggests that exacerbations (i) may not be associ-
ated with specific changes in airway bacterial communities; (ii)
may be associated with changes in only a few OTUs and/or very
minor changes in several OTUs; or (iii) may result primarily
from host-specific factors such as the nature and degree of in-
flammatory response to some as yet undefined stimulus. We also
found no significant changes in total bacterial density by quan-
titative PCR in samples based on clinical state, suggesting that
the reduction in some OTUs with antibiotic treatment may be
offset by an increase in other, possibly more resistant, OTUs. It is
important to note, however, that our quantitative PCR analysis
did not differentiate between live and dead bacterial cells (12).
Thus, it is likely that measures of bacterial density, particularly in
samples obtained during antibiotic therapy, represent both viable
and dead bacteria. Whether this distinction is important with
respect to host inflammatory response and disease progression
remains unclear.
It is clear from our results and those of others (5, 6) that, as
most persons with CF age, lung function typically declines, anti-
biotic therapy both accumulates and accelerates, and the diversity
of the airway community decreases. However, these confounding
variables present a challenge to establishing a simple linear cause-
and-effect relationship between the progression of lung disease
and decreasing community diversity. Although age, lung function
(%FEV1), and antibiotic use were all significantly correlated with
community diversity in our study, we found that the effects of age
and lung function lost significance when controlled for antibiotic
use, suggesting that antibiotic therapy is the stronger driver of
decreasing diversity. More robust models of antibiotic use in CF
that incorporate antibiotic class, spectrum of activity, route of de-
livery, synergistic or antagonistic interactions, and duration of
therapy are needed to provide a more precise understanding of
the impact of antibiotic use on microbial community diversity.
Although we found considerable overlap in the community
structures from all six patients, pairwise analyses using PCoA
and AMOVA showed significant community differences between
patient pairs (with the exception of patients P2 and P3), sug-
gesting that interpatient variability in community structures
exceeds intrapatient variability in longitudinal sample sets. When
pairwise analyses were performed on subsets of samples based on
disease stage (Fig. S8 and Table S4), we found that communities
from the three progressing patients become more or less distinct
in the advanced stage of disease, depending on the dominant
species. More specifically, the advanced-stage communities in
samples from patient P1, which were dominated by Achromo-
bacter, were quite distinct from those of patients P2 and P3, which
were dominated by Pseudomonas. This result suggests that, as
community diversity decreases in the advanced stage of disease,
community structures adopt a smaller number of distinct profiles,
mainly described by the species that dominates the community.
Our analyses of serial samples from individual patients rein-
forced the impact of antibiotic therapy on community structure
dynamics. BC-based PCoA plots showed marked movement of
communities in samples obtained during antibiotic therapy for
exacerbation relative to other samples, with the correlation be-
tween BC distance and antibiotic use exceeding that of either BC
distance and age or BC distance and %FEV1. Our results also
suggest that CF airways communities are resilient after perturba-
tion by antibiotics. PCoA plots of communities in serial samples
from the three progressing patients generally show communities in
treatment recovery samples returning to profiles resembling the
communities in samples obtained before therapy, indicating that
resilience, rather than stochastic reassembly of depleted commu-
nities with new species, drives community dynamics in CF. A more
complete assessment of the resilience of CF airway communities
will require analysis of a larger set of samples from around the time
of exacerbations. An important question to address in this regard is
whether the dynamic range of communities changes as diversity
decreases with disease progression. It may be reasonable to expect
that, as airway communities become increasingly constrained by
repeated antibiotic use, they may exhibit greater resistance to
further perturbation, particularly if the community becomes re-
stricted to a small number of highly antibiotic-resistant species.
Our study reinforces the dominant role of Pseudomonas as
a constituent of the CF airway microbiota. Pseudomonas was
identified in all six patients and quite often represented the most
abundant species in individual samples. Of particular note, the
communities in patients S1 and S2 were dominated almost uni-
formly by Pseudomonas during 8–9 y of clinical stability, in-
dicating that the presence of Pseudomonas, even in relatively
high abundance, does not necessarily predict poor clinical out-
come. Additional analyses that allow quantitative assessment of
potential fluctuations in the absolute density of P. aeruginosa are
required to understand better the ecology and clinical impact of
this species in CF. Our study also reaffirms that several anaer-
obic species, including a number of Veillonella and Prevotella
species, are common and relatively abundant members of the
airway microbiota in CF (13). The facultative anaerobic species
of the S. milleri group (S. anginosus, S. constellatus, and S.
intermedius) deserve particular attention. Using both culture and
culture-independent methods, Sibley and colleagues (4) found
that these species are detected frequently in CF respiratory
samples and may be associated with clinical decline in health.
Our results support these observations: S. milleri species were
both persistent (present in most samples) and relatively abun-
dant in all patients included in our study.
Our results support the recent observations by van der Gast
and colleagues (2) that the CF airway bacterial metacommunity
can be partitioned into two groups. One group is comprised of
taxa that are prevalent and typically abundant; the other group
consists of less commonly found species occurring in low abun-
dance. We, too, found a positive correlation between OTU oc-
currence and relative abundance; communities in our six patients
were dominated most often by Pseudomonas, S. milleri species,
and strictly anaerobic species. Again, however, our results high-
light the importance of taking clinical state into account in char-
acterizing the airway bacterial community in this regard. We ob-
served that a greater number of OTUs met our definition of
persistent, which considers both rate of occurrence and relative
abundance, when samples were limited to those obtained in the
absence of antibiotic therapy.
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Given these observations, it is important to note that themethod
of DNA extraction may have a significant impact on measures
of the relative abundance of specific taxa. For example, we have
shown recently that a method of DNA extraction that does not
include the use of lysozyme and lysostaphin significantly under-
represents the abundance of Staphylococcus in CF sputum samples
(14). Thus, firm conclusions regarding the relative abundance
of species in individual specimens must be made with caution.
In comparing communities across multiple specimens, however, a
given method of DNA extraction should impart equal bias across
all samples; therefore, observed intersample differences would not
be expected to be the result of the methodology used.
Finally, by using quantitative PCR we have shown, similar to
the recent report by Stressmann and colleagues (15), that the
total bacterial density in the airway does not increase significantly
at the time of pulmonary exacerbation. Our study extends these
observations to show further that, as bacterial community di-
versity decreases with advancing age, progression of lung disease,
and increasing antibiotic use, overall bacterial density remains
relatively stable over prolonged periods of time. Our data suggest
that, as community diversity decreases, the density of the re-
maining species increases to maintain a stable airway bacterial
load. This result is most evident in the terminal treatment samples
from patients P1 and P3, wherein bacterial density remained high
(108–109 copies/mL) in the context of markedly species-restricted
airway communities and intensive antibiotic therapy.
In summary, this study describes the structure and dynamics
of airway bacterial communities in persons with CF over periods
of several years, relating these measures to changes in patients’
clinical status and treatment. We describe diverse communities
that, nevertheless, often are dominated by a few select genera.
Our longitudinal analysis shows that high levels of diversity can be
maintained for prolonged periods of time in patients with a mildly
aggressive disease phenotype but that diversity decreases in
patients with more typical progressive lung disease, being driven
primarily by antibiotic therapy. We found that interpatient vari-
ability in community structures exceeds intrapatient variability
in serial samples, indicating that patients harbor distinguishable
communities. With decreasing diversity, communities converge
to a narrower spectrum of distinct profiles, each being described
by the dominant species present. Our analyses suggest that CF
airway communities are resilient after antibiotic perturbation
and that overall bacterial density remains relatively stable de-
spite markedly decreasing diversity in the advanced stages of lung
disease. Significant changes in community structure, diversity, or
bacterial density at the time of pulmonary exacerbation were not
observed. We have shown that patient clinical state and disease
stage are critical in interpreting changes in the diversity and struc-
ture of the airway community, underscoring the importance of
longitudinal studies in determining patterns of association be-
tween the CF airway microbiome and lung disease.
Materials and Methods
Patients, Sputum Specimens, and Medical Record Review. Sputum sample
collection and medical record review were approved by the University of
Michigan Institutional Review Board. Each of the 126 sputum specimens
included in this study was assigned to one of four clinical states based on
medical record review (see SI Materials and Methods for details). Antibiotic
load was calculated as the sum of the number of days a patient received an
antibiotic within the 30 d before sample collection (see SI Materials and
Methods for details).
DNA Extraction and Quantitative PCR. DNA was extracted from sputum
samples by treatment with Sputolysin (EMD Chemicals), mechanical disrup-
tion, and processing on an automated nucleic acid purification platform
(MagNA Pure Compact System; Roche) (see SI Materials and Methods for
details). Total bacterial load was measured by quantitative PCR using the
universal primer/probe set of Nadkarni et al. (16) targeting the bacterial 16S
rRNA gene (see SI Materials and Methods for details).
DNA Sequencing and Data Analyses. Bar-coded pyrosequencing of the 16S
rRNA V3–V5 hypervariable region was performed by the Human Genome
Sequencing Center at Baylor College of Medicine using protocols devel-
oped for the Human Microbiome Project (http://www.hmpdacc.org/tools_
protocols/tools_protocols.php). The software package mothur v. 1.21 (17)
was used to process sequences and to calculate alpha and beta diversities.
Statistical analyses were performed in PASW Statistics 18 and R packages
vegan and ade4 (see SI Materials and Methods for details).
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